AVR 1.29% $17.97 anteris technologies ltd

Response received from Wayne on LinkedIn, page-33

  1. 611 Posts.
    lightbulb Created with Sketch. 122
    Thanks @garthdaisy.

    I think it's important to stress that this product is not a competitor to Admedus but rather a collaborator. The patent you've linked to specifically states that Cardiocel is a suitable material to use in conjunction with this scaffold, implying the recommended use of Cardiocel with the NeoChord product:

    "In some embodiments , the region between the valve plane struts, that is in the coaptation zone of the leaflets can include a solid biomaterial positioned therein to increase the surface area for leaflet coaptation , which is particularly useful for patients suffering from functional mitral valve regurgitation . In some such embodiments , the use of web in valve to prevent regurgitation ultimately retrains and reshapes the valve such that the valve leaflets and annulus naturally revert to a more natural configuration to obtain proper coaptation over time . In such embodiments , the biomaterial can be a bioabsorbable material that is absorbed into the body over time . Suitable biomaterials can include , for example , bovine pericardium and CardioCel® ."
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.